Background: Mycobacterium abscessus complex (MABC) is the most common non-tuberculous mycobacterium that causes complicated skin and soft tissue infections (cSSTIs). The selection of antimycobacterial agents for successful treatment of such infections is a critical issue.
Introduction
Organisms of the Mycobacterium abscessus complex (MABC), belonging to the group of rapidly growing mycobacteria, are ubiquitous in soil and water. 1 MABC is recognized as being the second most common major pathogen responsible for pulmonary infection in Asian and Western countries. 2, 3 In addition, MABC is the most common non-tuberculous mycobacterial pathogen causing complicated skin and soft tissue infections (cSSTIs). 2, [4] [5] [6] The high drug resistance of MABC arises from both intrinsic as well as acquired resistance, and therefore MABC infection has become a serious emerging health issue. Currently, MABC is divided into three subspecies: M. abscessus subsp. abscessus (MAB), M. abscessus subsp. massiliense (MMA) and M. abscessus subsp. bolletii (MBO). 8 Optimal treatment regimens for MABC have not yet been established due to its multidrug resistance. MMA has been reported to be susceptible to clarithromycin. However, other reports have shown that MAB is less responsive to clarithromycin therapy. 7 Because of the high degree of drug resistance, antimycobacterial treatment for MABC is time-consuming and costly. In Taiwan, only a few reports concerning antimicrobial susceptibility testing for MABC have been published. 9 Furthermore, epidemiological studies examining MABC cSSTIs are scarce. 2 The goal of this study was to explore the antimicrobial susceptibilities of MABC isolates and thereby identify the most potentially useful antimycobacterial agents.
Materials and methods

Clinical strains
A total of 67 MABC clinical strains were isolated from patients with deep soft tissue infections at Chang Gung Memorial Hospital, Lin-Kou Centre in Taiwan, between 1 August 2012 and 31 March 2016. The pigmentation and morphology of these bacterial colonies were observed and recorded.
secA1, rpoB, hsp65, erm(41) and rrl partial gene sequencing Genomic DNA was extracted from MABC cultures for identification based on the sequences of the genes secA1, rpoB and hsp65.
10 Details of the PCR method used were described previously by Zelazny et al. 11 Sequencing of erm(41) and rrl was performed using the methods described by Maurer et al. 12 Sequences were analysed and compared with the NCBI database using a BLAST search (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
Drug susceptibility testing (DST)
DST was performed using the broth microdilution method with Sensititre RAPMYCOI MIC plates (Thermo Fisher) as recommended by the CLSI. 13 The antimicrobial agents tested included amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, linezolid, minocycline, moxifloxacin, trimethoprim/sulfamethoxazole and tigecycline. The MICs of clarithromycin were read at an early time (ERT; usually between the third and fifth day) if control growth was positive, and at a late time (LRT; on the 14th day of incubation) to detect inducible macrolide resistance. Susceptible, intermediately susceptible and resistant breakpoints followed CLSI guidelines, with the exception of the breakpoint for tigecycline, which was not provided by CLSI. 13 The MICs of Mycobacterium peregrinum ATCC 700686 were used as the quality control.
Statistical analysis
All calculations were performed with STATA statistical software, version 14 (Stata Corporation, College Station, TX, USA). The Mann-Whitney U-test was used for intergroup comparisons of continuous variables. Categorical variables were compared using the v 2 test or Fisher's exact test. A P value of ,0.05 was considered statistically significant.
Results
Morphology and pigmentation of MABC isolates
Two types of morphology were observed among the colonies, these being either smooth (45; 67.2%) or rough (22; 32.8%).
The proportion of smooth to rough for MAB was 21 to 7, while for MMA it was 23 to 15 (P " 0.22). Only one MBO had a smooth colony. All strains had a white colour.
secA1, rpoB, hsp65, erm(41) and rrl gene sequencing analyses
The proportions of MAB, MMA and MBO to the total number MABC isolates were 41.8% (28/67), 56.7% (38/67) and 1.5% (1/67), respectively. Among the 28 MAB isolates, there were 10 C28 variants and 18 T28 variants of the erm(41) gene. All 38 MMA isolates harboured a truncated erm(41). In contrast, the MBO strain possessed the erm(41) T28 sequence. Among the 28 MAB isolates and 1 MBO isolate, no point mutations were found in the rrl gene. In contrast, two MMA isolates (from the same patient) harboured an A2059G point mutation among the 38 isolates examined.
DST
The susceptibility patterns to 11 antimycobacterial agents of the 67 MABC isolates, including MAB, MMA and MBO, are shown in Table 1 .
The intermediately susceptible and resistant rates for ciprofloxacin, doxycycline, imipenem, linezolid, minocycline, moxifloxacin and trimethoprim/sulfamethoxazole were high for both MAB and MMA. The MBO isolate was also resistant to ciprofloxacin, doxycycline, imipenem, linezolid, minocycline, moxifloxacin and trimethoprim/sulfamethoxazole.
Cefoxitin showed intermediate antimicrobial activity against MAB and MMA. The intermediately susceptible rates for MAB and MMA were 85.7% (24/28) and 68.4% (26/38), respectively. Moreover, the resistance rates for MAB and MMA were 10.7% (3/28) and 28.9% (11/38), respectively.
Amikacin and clarithromycin showed good activities against both MAB and MMA. The resistance rates to amikacin for MAB and MMA were 7.1% (2/28) and 5.3% (2/38), respectively. The MIC 50 and MIC 90 values of clarithromycin for MAB were 0.25 and 8 mg/L, respectively, and were 0.12 and 0.5 mg/L for MMA, respectively. The resistant rates for MAB and MMA to clarithromycin ERT were 10.7% (3/28) and 5.3% (2/38), respectively. However, we noticed that 2 MMA strains differed from the other 36 MMA strains due to their high MICs for clarithromycin, which were .16 mg/L at the ERT.
Furthermore, we found that the majority of the MMA isolates (18/28) were erm(41) T28 sequevars. The MIC 50 and MIC 90 of clarithromycin LRT were .16 mg/L for MAB, and were 0.25 and 1 mg/L, respectively, for MMA. The resistance rates of MAB and MMA to clarithromycin at the LRT were 57.1% (16/28) and 5.3% (2/38), respectively (P , 0.005). The MIC 50 and MIC 90 of tigecycline for both MAB and MMA was 0.5 and 1 mg/L, respectively. The MIC of tigecycline for MBO was 0.25 mg/L.
Discussion
MABC skin and soft tissue infection is often found to be associated with cosmetic surgery, other surgical procedures and trauma. MABC manifests itself as abscess formation, chronic ulcers or disseminated disease. 2 The diagnosis and treatment of pulmonary MABC infection must fulfil the criteria proposed by the American Thoracic Society; 3 in contrast, any isolates from skin and soft tissues are always Antimicrobial resistance in M. abscessus complex in Taiwan JAC considered to be clinically significant and need to be treated. The treatment duration for MABC cSSTIs can frequently last as long as 6-12 months. 3 The selection of antimycobacterial agents and treatment of MABC cSSTIs is becoming an important issue.
In this study, MMA and MAB were largely resistant to ciprofloxacin, doxycycline, minocycline and moxifloxacin. In addition, it is worth noting that our strains were more resistant to cefoxitin, imipenem and linezolid than the strains that were studied by Mougari et al.
14 In some case reports, the MABCs derived from superficial skin and soft tissue infections have been successfully cured by the administration of cefoxitin.
1,2 However, most of the MABC strains in the present study were intermediately susceptible or resistant to cefoxitin. Regardless, because of the short half-life of cefoxitin and the necessity for long-term treatment of MABC skin and soft tissue infections, cefoxitin is not suitable as an agent for outpatient antimicrobial therapy (OPAT). Lee et al.
Although there is no accurate breakpoint for MABC treatment with tigecycline that is recommended by CLSI, the MIC 90 of tigecycline for our strains was 1 mg/L, indicating that tigecycline also had good activity against MABC.
Based on a published study, MABC infections were usually poorly responsive to macrolides because of inducible and/or acquired resistance mechanisms. 15 Nash et al. 16 proposed that the erm(41) T28 polymorphism was related to inducible macrolide resistance in MABC at an LRT. This was confirmed in our study, where more than half (16/28) of the MAB strains were resistant to clarithromycin at an LRT. Intriguingly, two MAB erm(41) T28 sequevars were sensitive to clarithromycin at an LRT (nucleotide and amino acid sequences of two isolates are shown in Figure S1 , available as Supplementary data at JAC Online). MMA generally possesses a truncated erm(41) gene 2, 15 and therefore it is mostly susceptible to clarithromycin, but we found that the two macrolide-resistant isolates possessed a point mutation in the rrl gene (A2059G).
In this study, we have therefore identified potentially effective drug regimens, which include the use of clarithromycin, amikacin and tigecycline, for the treatment of MABC in Taiwan. Our study results were based on DST, which may not correlate with clinical outcomes. In this regard, a study by Koh et al. 17 reported that clinical outcomes did not correlate with the susceptibility to cefoxitin or imipenem.
MMA strains and MAB erm(41) C28 sequevars are mostly susceptible to clarithromycin, amikacin and probably also to tigecycline. In contrast, the MBO strain and the MAB erm(41) T28 sequevars are mostly susceptible to amikacin and probably also to tigecycline. Huang et al. 18 reported the synergistic activities of tigecycline with clarithromycin or amikacin against MABC. Therefore, we suggest the use of at least two or more antimycobacterial combination regimens for MABC cSSTIs in order to overcome multidrug resistance. Moreover, both amikacin and tigecycline can be administered once daily and prescribed as part of OPAT to reduce the length of hospitalization. 19, 20 The clinical efficacy of other antimycobacterial agents has not yet been validated. In conclusion, clarithromycin, amikacin and tigecycline are all good choices for the treatment for MABC cSSTIs in Taiwan, but further clinical study is also warranted.
